NeuroSense Therapeutics Receives Nasdaq Minimum Bid Price and Market Value Deficiency Notifications

On April 3, 2026, NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) announced that it received two deficiency notification letters from the Nasdaq Stock Market LLC on April 2, 2026. The notifications indicate that the company is currently not in compliance with Nasdaq Listing Rule 5550(a)(2), requiring a minimum bid price of $1.00 per share, and Nasdaq Listing Rule 5550(b)(2), requiring a minimum market value of listed securities (MVLS) of $35 million. These deficiencies occurred because the company's ordinary shares remained below these thresholds for 30 consecutive business days from February 18, 2026, through March 31, 2026. The notifications have no immediate impact on the listing or trading of the company's securities. NeuroSense has been granted a 180-day compliance period, ending September 29, 2026, to regain compliance. To do so, the company's ordinary shares must maintain a closing bid price of at least $1.00 and an MVLS of at least $35 million for a minimum of 10 consecutive business days. The company is currently evaluating strategic options to address these requirements.